-
Something wrong with this record ?
BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas
M Reinis
Current opinion in molecular therapeutics.
2008 ;
10 (5) :
526-534.
Language English Country Great Britain
Document type Review
Persistent link
https://www.medvik.cz/link/bmc11004996
- MeSH
- Lymphoma, B-Cell immunology therapy MeSH
- Granulocyte-Macrophage Colony-Stimulating Factor administration & dosage MeSH
- Lymphoma, Follicular immunology therapy MeSH
- Clinical Trials, Phase I as Topic MeSH
- Clinical Trials, Phase II as Topic MeSH
- Humans MeSH
- Mice MeSH
- Cancer Vaccines administration & dosage MeSH
- Vaccination methods MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Review MeSH
Biovest International Inc (a subsidiary of Accentia BioPharmaceuticals Inc), under license from Stanford University, is developing BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas that, in combination with GM-CSF, exclusively targets cancerous B-cells by raising an immune response to tumor-specific immunoglobulin proteins called idiotypes, for the potential treatment of follicular non-Hodgkin's lymphoma (NHL). Phase I and II clinical trials demonstrated the immunogenicity, safety and therapeutic efficacy of BiovaxID. Phase III clinical trials in NHL were ongoing at the time of publication.
- 000
- 02061naa 2200349 a 4500
- 001
- bmc11004996
- 003
- CZ-PrNML
- 005
- 20121122112036.0
- 008
- 110311s2008 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Reiniš, Milan $7 xx0083033
- 245 10
- $a BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas / $c M Reinis
- 314 __
- $a Institute of Molecular Genetics AS CR, vvi, Videnska 1083, Prague 4, CZ-14220, Czech Republic. reinis@img.cas.cz
- 520 9_
- $a Biovest International Inc (a subsidiary of Accentia BioPharmaceuticals Inc), under license from Stanford University, is developing BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas that, in combination with GM-CSF, exclusively targets cancerous B-cells by raising an immune response to tumor-specific immunoglobulin proteins called idiotypes, for the potential treatment of follicular non-Hodgkin's lymphoma (NHL). Phase I and II clinical trials demonstrated the immunogenicity, safety and therapeutic efficacy of BiovaxID. Phase III clinical trials in NHL were ongoing at the time of publication.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové vakcíny $x aplikace a dávkování $7 D019496
- 650 _2
- $a klinické zkoušky, fáze I jako téma $7 D017321
- 650 _2
- $a klinické zkoušky, fáze II jako téma $7 D017322
- 650 _2
- $a faktor stimulující granulocyto-makrofágové kolonie $x aplikace a dávkování $7 D016178
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a B-buněčný lymfom $x imunologie $x terapie $7 D016393
- 650 _2
- $a folikulární lymfom $x imunologie $x terapie $7 D008224
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a vakcinace $x metody $7 D014611
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $t Current Opinion in Molecular Therapeutics $w MED00173598 $g Roč. 10, č. 5 (2008), s. 526-534 $x 1464-8431
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20110414094026 $b ABA008
- 991 __
- $a 20121122112059 $b ABA008
- 999 __
- $a ok $b bmc $g 832864 $s 697036
- BAS __
- $a 3
- BMC __
- $a 2008 $b 10 $c 5 $d 526-534 $i 1464-8431 $m Current opinion in molecular therapeutics $n Curr Opin Mol Ther $x MED00173598
- LZP __
- $a 2011-4B/vtme
